구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 4개 · 임상 갱신 필요 2개 · Data Tier에서 열림
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | tezepelumab (Tezspire, AMG 157, MEDI9929, tezepelumab-ekko) AstraZeneca / Amgen·TSLP (thymic stromal lymphopoietin… 47 trials·t½ ~26 days | Inhaled corticosteroid (ICS, Inhaled corticosteroid, Inhaled corticosteroid (ICS) therapy) Sanofi·Asthma 243 trials | ||
|---|---|---|---|---|
Overview Program | Dupixent (dupilumab) | Tezspire (tezepelumab) | Inhaled corticosteroid (ICS) therapy | AIN457 (secukinumab) |
Overview Company | Sanofi / Regeneron | AstraZeneca / Amgen | Sanofi | Novartis |
Overview Modality | ANTIBODY | ANTIBODY | ANTIBODY | ANTIBODY |
Overview Target | IL-4Rα | TSLP (thymic stromal lymphopoietin) | Asthma | Psoriatic Arthritis |
Overview Indication | Atopic dermatitis, asthma, CRSwNP, EoE, prurigo nodularis | Severe asthma add-on maintenance, chronic rhinosinusitis with nasal polyps | Asthma | Asthma |
Overview Phase | APPROVED | APPROVED | PHASE_3 | PHASE_3 |
Overview Status | APPROVED | APPROVED | ACTIVE | ACTIVE |
Overview Content status | Curated Core | Curated Core | Limited Data | Limited Data |
Overview Data Confidence | Data Confidence · High | Data Confidence · High | Data Confidence · Low | Data Confidence · Low |
Overview Development Signal | Development Signal · Established | Development Signal · Established | Development Signal · Emerging | Development Signal · Emerging |
Overview Approval status | FDA approved | FDA approved | Investigational | Investigational |
Positioning Key differentiator | Novel targets under investigation include MRGPRs, PARs, KIT receptors, OX-40, and sodium channels | Acting upstream of IL-4/IL-5/IL-13 covers both eosinophilic and low-eosinophil asthma, unlike downstream type-2 blockers. | — | — |
Positioning Known limitation | Non-Type 2 inflammation and inadequate trough levels. | Non-inflammatory structural airway disease does not respond to cytokine blockade. | — | — |
Positioning Development positioning | — | The phenotype-agnostic option versus Dupixent, Nucala, and Fasenra. | — | — |
MoA Mechanism | Dupilumab binds IL-4Rα subunit shared by IL-4 type I and IL-13 type II receptors, inhibiting IL-4 and IL-13 signaling, reducing Type 2 inflammation (IgE, eosinophils, Th2 cytokines). | Neutralizes epithelial-derived TSLP, blocking the alarmin signal that initiates dendritic-cell and ILC2 activation and downstream type-2 and non-type-2 airway inflammation. | , comparative clinical efficacy, prescribing patterns, safety outcomes, and future directions for individualized therapy | Targeted immunotherapies provide effective interventions by disrupting these cytokine-driven pathway |
MoA Biomarker | biomarkers and clinical characteristics and highlight the need for standardized, methodologically rigorous fu | Blood eosinophils, FeNO, total IgE fall on treatment but none is required for eligibility. | Biomarkers | biomarkers and optimize therapeutic strategies |
PK/PD Half-life | ~14 days (300 mg q2w) | ~26 days | — | 31 h |
PK/PD Species | Mouse, EASI-75, peak pruritus NRS reduction | Cynomolgus monkey, Annualized exacerbation rate, pre-bronchodilator FEV1, FeNO, blood eosinophils | Mouse | Rat, Human |
PK/PD Animal (cat.) | Mouse | Human, NHP | Mouse | Human, Rat |
PK/PD Experiment | PD | Pharmacokinetic | PD | PD |
Toxicology Species | Mouse | Cynomolgus monkey | Mouse | Rat, Human |
Toxicology Animal (cat.) | — | — | Mouse | Human, Rat |
Toxicology Major finding | Conjunctivitis, injection-site reactions, eosinophilia; herpes zoster caution. | Generally well tolerated — pharyngitis, arthralgia, back pain, and injection-site reactions. Hypersensitivity occurs rarely; live vaccines should be considered before starting. | Comparing the Safety Profiles of Vaginally Administered Misoprostol and Dinoprostone: A Retrospective Pharmacovigilance Study.. Misoprostol and dinoprostone are the most commonly used agents for cervical ripening during labour induction. However, comparative safety data remain limited, particularly regarding rare adverse events and off-label use. Data were obtained from the FDA Adverse Event Repor… | Effectiveness of brodalumab in biologic-experienced adults with moderate to severe plaque psoriasis: a focused narrative review.. To summarize recent literature evaluating treatment outcomes in adults with plaque psoriasis who switched to brodalumab from a different biologic because of treatment failure (inadequate initial response/loss of an adequate initial response) and/or adverse events. Relev… |
Toxicology CRS | N/A | N/A | — | — |
Clinical Safety signal | Conjunctivitis, injection-site reactions, eosinophilia; herpes zoster caution. | Generally well tolerated — pharyngitis, arthralgia, back pain, and injection-site reactions. Hypersensitivity occurs rarely; live vaccines should be considered before starting. | Comparing the Safety Profiles of Vaginally Administered Misoprostol and Dinoprostone: A Retrospective Pharmacovigilance Study.. Misoprostol and dinoprostone are the most commonly used agents for cervical ripening during labour induction. However, comparative safety data remain limited, particularly regarding rare adverse events and off-label use. Data were obtained from the FDA Adverse Event Repor… | Effectiveness of brodalumab in biologic-experienced adults with moderate to severe plaque psoriasis: a focused narrative review.. To summarize recent literature evaluating treatment outcomes in adults with plaque psoriasis who switched to brodalumab from a different biologic because of treatment failure (inadequate initial response/loss of an adequate initial response) and/or adverse events. Relev… |
Clinical Selected reported efficacy | — | 56% | — | 9% |
Clinical Result source | ClinicalTrials.gov NCT02912468 | NAVIGATOR (NCT03347279) | ClinicalTrials.gov NCT00529529 | ClinicalTrials.gov NCT03131570 |
Clinical Program phase | APPROVED | APPROVED | PHASE_3 | PHASE_3 |
Clinical Trial activity | No active/completed counts | No active/completed counts | No active/completed counts | No active/completed counts |
Clinical Trial ref | NCT02912468 | NCT03347279 | NCT00529529 | NCT03131570 |
Preclinical Animal (cat.) | — | NHP | — | — |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 4개 · 임상 갱신 필요 2개 · Data Tier에서 열림
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | tezepelumab (Tezspire, AMG 157, MEDI9929, tezepelumab-ekko) AstraZeneca / Amgen·TSLP (thymic stromal lymphopoietin… 47 trials·t½ ~26 days | Inhaled corticosteroid (ICS, Inhaled corticosteroid, Inhaled corticosteroid (ICS) therapy) Sanofi·Asthma 243 trials | ||
|---|---|---|---|---|
Overview Program | Dupixent (dupilumab) | Tezspire (tezepelumab) | Inhaled corticosteroid (ICS) therapy | AIN457 (secukinumab) |
Overview Company | Sanofi / Regeneron | AstraZeneca / Amgen | Sanofi | Novartis |
Overview Modality | ANTIBODY | ANTIBODY | ANTIBODY | ANTIBODY |
Overview Target | IL-4Rα | TSLP (thymic stromal lymphopoietin) | Asthma | Psoriatic Arthritis |
Overview Indication | Atopic dermatitis, asthma, CRSwNP, EoE, prurigo nodularis | Severe asthma add-on maintenance, chronic rhinosinusitis with nasal polyps | Asthma | Asthma |
Overview Phase | APPROVED | APPROVED | PHASE_3 | PHASE_3 |
Overview Status | APPROVED | APPROVED | ACTIVE | ACTIVE |
Overview Content status | Curated Core | Curated Core | Limited Data | Limited Data |
Overview Data Confidence | Data Confidence · High | Data Confidence · High | Data Confidence · Low | Data Confidence · Low |
Overview Development Signal | Development Signal · Established | Development Signal · Established | Development Signal · Emerging | Development Signal · Emerging |
Overview Approval status | FDA approved | FDA approved | Investigational | Investigational |
Positioning Key differentiator | Novel targets under investigation include MRGPRs, PARs, KIT receptors, OX-40, and sodium channels | Acting upstream of IL-4/IL-5/IL-13 covers both eosinophilic and low-eosinophil asthma, unlike downstream type-2 blockers. | — | — |
Positioning Known limitation | Non-Type 2 inflammation and inadequate trough levels. | Non-inflammatory structural airway disease does not respond to cytokine blockade. | — | — |
Positioning Development positioning | — | The phenotype-agnostic option versus Dupixent, Nucala, and Fasenra. | — | — |
MoA Mechanism | Dupilumab binds IL-4Rα subunit shared by IL-4 type I and IL-13 type II receptors, inhibiting IL-4 and IL-13 signaling, reducing Type 2 inflammation (IgE, eosinophils, Th2 cytokines). | Neutralizes epithelial-derived TSLP, blocking the alarmin signal that initiates dendritic-cell and ILC2 activation and downstream type-2 and non-type-2 airway inflammation. | , comparative clinical efficacy, prescribing patterns, safety outcomes, and future directions for individualized therapy | Targeted immunotherapies provide effective interventions by disrupting these cytokine-driven pathway |
MoA Biomarker | biomarkers and clinical characteristics and highlight the need for standardized, methodologically rigorous fu | Blood eosinophils, FeNO, total IgE fall on treatment but none is required for eligibility. | Biomarkers | biomarkers and optimize therapeutic strategies |
PK/PD Half-life | ~14 days (300 mg q2w) | ~26 days | — | 31 h |
PK/PD Species | Mouse, EASI-75, peak pruritus NRS reduction | Cynomolgus monkey, Annualized exacerbation rate, pre-bronchodilator FEV1, FeNO, blood eosinophils | Mouse | Rat, Human |
PK/PD Animal (cat.) | Mouse | Human, NHP | Mouse | Human, Rat |
PK/PD Experiment | PD | Pharmacokinetic | PD | PD |
Toxicology Species | Mouse | Cynomolgus monkey | Mouse | Rat, Human |
Toxicology Animal (cat.) | — | — | Mouse | Human, Rat |
Toxicology Major finding | Conjunctivitis, injection-site reactions, eosinophilia; herpes zoster caution. | Generally well tolerated — pharyngitis, arthralgia, back pain, and injection-site reactions. Hypersensitivity occurs rarely; live vaccines should be considered before starting. | Comparing the Safety Profiles of Vaginally Administered Misoprostol and Dinoprostone: A Retrospective Pharmacovigilance Study.. Misoprostol and dinoprostone are the most commonly used agents for cervical ripening during labour induction. However, comparative safety data remain limited, particularly regarding rare adverse events and off-label use. Data were obtained from the FDA Adverse Event Repor… | Effectiveness of brodalumab in biologic-experienced adults with moderate to severe plaque psoriasis: a focused narrative review.. To summarize recent literature evaluating treatment outcomes in adults with plaque psoriasis who switched to brodalumab from a different biologic because of treatment failure (inadequate initial response/loss of an adequate initial response) and/or adverse events. Relev… |
Toxicology CRS | N/A | N/A | — | — |
Clinical Safety signal | Conjunctivitis, injection-site reactions, eosinophilia; herpes zoster caution. | Generally well tolerated — pharyngitis, arthralgia, back pain, and injection-site reactions. Hypersensitivity occurs rarely; live vaccines should be considered before starting. | Comparing the Safety Profiles of Vaginally Administered Misoprostol and Dinoprostone: A Retrospective Pharmacovigilance Study.. Misoprostol and dinoprostone are the most commonly used agents for cervical ripening during labour induction. However, comparative safety data remain limited, particularly regarding rare adverse events and off-label use. Data were obtained from the FDA Adverse Event Repor… | Effectiveness of brodalumab in biologic-experienced adults with moderate to severe plaque psoriasis: a focused narrative review.. To summarize recent literature evaluating treatment outcomes in adults with plaque psoriasis who switched to brodalumab from a different biologic because of treatment failure (inadequate initial response/loss of an adequate initial response) and/or adverse events. Relev… |
Clinical Selected reported efficacy | — | 56% | — | 9% |
Clinical Result source | ClinicalTrials.gov NCT02912468 | NAVIGATOR (NCT03347279) | ClinicalTrials.gov NCT00529529 | ClinicalTrials.gov NCT03131570 |
Clinical Program phase | APPROVED | APPROVED | PHASE_3 | PHASE_3 |
Clinical Trial activity | No active/completed counts | No active/completed counts | No active/completed counts | No active/completed counts |
Clinical Trial ref | NCT02912468 | NCT03347279 | NCT00529529 | NCT03131570 |
Preclinical Animal (cat.) | — | NHP | — | — |
추천 비교
추천 비교